Dosing & Administration

A portable, subcutaneous treatment that can be carried with patients every day

FIRAZYR (icatibant) is indicated for the treatment of acute attacks of hereditary angioedema (HAE) in adults 18 years of age and older.1

FIRAZYR is the first prefilled, self-administered, subcutaneous injection to treat acute HAE attacks, that is ready to use as soon as patients recognize the symptoms of an attack1

  • Requires no reconstitution/mixing, no dose calculation, no special handling, no dose titration, and no refrigeration1
    • FIRAZYR may be stored at room temperature. Store between 36°F and 77°F (2°C and 25°C).
  • FIRAZYR is administered over at least 30 seconds into the abdominal area.1
  • Patients may self-administer FIRAZYR upon recognition of symptoms of an HAE attack, after training by a healthcare professional.1
  • FIRAZYR is available as a 3-mL, prefilled, single-use syringe (30 mg).1
  • If response is inadequate or symptoms recur, additional doses may be administered at intervals of 6 hours or longer.1
    • No more than 3 doses may be used in a 24-hour period
  • FIRAZYR is available in a convenient pack containing 3 cartons1
    • Single cartons are also available

FIRAZYR® product packaging, plus prefilled, single-use syringe.